Alnylam (ALNY) PT Cut to $58 at Jefferies

October 6, 2016 6:47 AM EDT
Get Alerts ALNY Hot Sheet
Price: $42.25 +3.53%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ALNY Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.

Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of revusiran Ph3 due to mortality imbalance. While longer follow-up would be needed to rule out similar safety concerns for the overall technology platform, the setback might be program/disease specific as suggested by our analysis. However, we see high risk for the ‘TTRsc02 program given seemingly lack of efficacy with revusiran. We lower PT to $58."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, Gena Wang

Add Your Comment